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Abstract 
 
Background: Applying the Kidney Disease Outcomes Quality Initiative definitions 
of chronic kidney disease (CKD), it appears that CKD is common. The increased 
recognition of CKD has brought with it the clinical challenge of translating into 
practice the implications for the patient and for service planning. To understand 
the clinical relevance and translate that into information to support individual 
patient care and service planning, we explored clinical outcomes in a large British 
community CKD cohort, identified through routine opportunistic testing, with 6 
years follow-up (~13,000 patient-years).  
 
Methods: A cohort had previously been identified with CKD - sustained reduced 
eGFR over at least 3 months and case-note review. Six year (13,339 patient-
years) follow up for Renal Replacement Therapy (RRT) initiation and death was 
achieved through data-linkage. Age and sex specific mortality rates were 
compared to the general population.    
 
Results: Of 3414 individuals (most stage 3b-5), median age 78.6 years, followed 
for 13,339 patient-years, 170 (5%) initiated RRT and 2024 (59%) died without 
initiating RRT. RRT initiation rates decreased with age from 14.33 to 0.65 per 100 
patient-years amongst those 15-25 years and 75-85 years at baseline but the 
actual numbers initiating RRT increased from 6 to 34 respectively.   RRT initiation 
rates were lower for female sex, absence of macroalbuminuria and less advanced 
CKD stage.  
Mortality rates increased with age from 1.9 to 33.8 per 100 patient-years for 
those aged 15-45 and over 85 years at baseline, an excess of 2 and 17 per 100 
patient-years over that of the general population respectively. However the 
increase in relative risk was 19 fold for those aged 15-45, and just two-fold in 
those over 85 years.  These data have been converted into simple tools for 
considering individual patients’ risk and informing service planning 
 
Conclusions: The contrast between relative and absolute risk for both RRT 
initiation and mortality by age group illustrate the difficulties for planning 
services. The challenge that now faces clinicians is how to appropriately identify 
which elderly with CKD are at high risk of poor outcome.  
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Introduction 
 
The principles of the Kidney Disease Outcomes Quality Initiative (KDOQI) 
guidelines(1), for the classification of chronic kidney disease (CKD) have been 
accepted internationally (2, 3) and have successfully highlighted the importance 
of CKD. By facilitating earlier diagnosis and management, the intention was to 
slow progression, improve outcomes and ultimately reduce the need for renal 
replacement therapy (RRT).  
With application of this classification, it appears that CKD is common (between 
3.8% and 11.1% of the population) (4) and, with an ageing population and 
increasing prevalence of diabetes, thought likely  to increase. High cardiovascular 
morbidity and mortality, and all-cause mortality among people with CKD (5-7) 
have led to calls for CKD screening as a public health measure. However despite 
the excess mortality and morbidity, not all patients with CKD die prematurely or 
initiate RRT (8). The lack of clarity about prognosis in CKD has sparked debate 
regarding whether the definition truly identifies those at risk of poor outcome or 
merely ‘label’ many, particularly the elderly, with disease, without a clear 
prognostic role (9). The increased recognition of CKD has brought with it the 
clinical challenge of translating into practice the implications for the patient and 
for service planning. 
 
To understand the clinical relevance of CKD and translate that into information to 
support individual patient care and service planning, we explored the relationship 
between RRT initiation, all-cause mortality rates and baseline characteristics in a 
large British community CKD cohort, identified through routine opportunistic 
testing, with 6 years follow-up (~13,000 patient-years).  
 
 
Methods 
 
The National Health Service (NHS) Grampian administrative region provides 
medical services to a well-defined population (n= 433,109, over 15 years of age 
in 2003) in North-East Scotland, with little use of external health services due to 
geographical remoteness. All biochemistry services (in-patient, community and 
private) are provided through two linked National External Quality Assessment 
Service monitored laboratories. All renal services (except transplantation up to 10 
days post-transplant) are provided from a single regional unit.  
 
In 2003, all adults (aged over 15 years) resident in the region, with abnormal 
renal function tests (creatinine above 150 µmol/l for men and 130 µmol/l for 
women measured from January to June) were identified (n=5538). Those on RRT 
were excluded. Results of those with acute kidney injury and early follow-up on 
those with CKD are reported elsewhere (10, 11), only those with CKD are 
reported here.  
 
GLOMMS-I - the cohort 
The first Grampian Laboratory Outcomes Mortality and Morbidity Study 
(GLOMMS-I) comprised a cohort of 3426 individuals with CKD from the 2003 
group. Individuals with CKD were identified by virtue of 3 either raised creatinine 
measurements (above the 150 µmol/l or 130 µmol/l threshold), or depressed 
estimated glomerular filtration rate (eGFR) values (median eGFR below 60 
ml/min/1.73m2) documented over at least 3 months either before or after the 
index creatinine. Case-note review provided baseline comorbidity. Regional health 
administration systems recorded all RRT provision, admissions, discharges, out-
patient attendances and death registrations within the region. Data linkage 
between these systems and the cohort took place to allow full follow up to the 
30th June 2009. 
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GLOMMS-I was approved by the University of Aberdeen Research Ethics 
Committee, the NHS Grampian Caldicott Guardian and discussed with the North 
of Scotland NHS Research Ethics Committee.  
 
Biochemistry 
Excretory renal function 
An individual’s first creatinine value above the threshold during the period 
January 2003 to June 2003 inclusively, was taken as the “index” creatinine. 
Serum creatinine values were measured using the kinetic Jaffe method (Siemens 
automated analyser using Siemens reagents) and were traceable over time to the 
isotope dilution mass spectrometry (IDMS) method. Estimated glomerular 
filtration rate (eGFR) values were calculated using the modified 4 variable MDRD 
equation suitable for use with IDMS traceable creatinine values. eGFR at “index” 
was used to assign a CKD stage.   
 
Proteinuria/ Albuminuria 
In the clinical dataset urinary protein creatinine ratio (PCR) and albumin 
creatinine ratio (ACR)were used, these were automatically calculated as part of 
the measurement of these urinary values on a Siemens automated analyser using 
Siemens reagents. Patients were defined as “untested”, “normoalbuminuric”, 
“microalbuminuric” or “macroalbuminuric” based on the single most recent 
(between 1999 and “index”) measurement of proteinuria or albuminuria. The 
thresholds for microalbuminuria were ≥2.5mg/mmol ACR for men, ≥3.5mg/mmol 
ACR for women; for macroalbuminuria ≥30mg/mmol ACR for both men and 
women, or ≥50mg/mmol PCR. No dipstick measurements were used.   
 
Baseline comorbidity & smoking status 
Nephrology specialists reviewed all case notes for important comorbidities and 
smoking status (table 1), data was extracted and data transfer checked by 
another individual.  
 
Clinical outcomes and follow-up 
The two outcomes of interest were:- initiatiation of renal replacement therapy 
(RRT) and all-cause mortality, with follow-up truncated at midnight 30th June 
2009 (6 years from the end of the “index” period). Date and cause of death as 
registered as ICD-10 codes with the General Registrar Office Scotland were 
recorded, as was date of chronic renal replacement therapy initiation (defined as 
per UK Renal Registry definition, no recovery of renal function within 90 days). 
Use of other NHS Grampian services (laboratory, out-patient or in-patient) within 
a year of study end was checked to estimate possible loss to follow-up. Of the 
3426 individuals in this CKD cohort, twelve died on the day of the index creatinine 
and were therefore excluded from the remainder of the analysis. 
 
Analysis 
Baseline characteristics were tabulated by gender and differences tested for using 
Chi squared or Mann Whitney test as appropriate. 
 
Renal survival was defined as not having initiated RRT, censoring at time of 
death, and was plotted using the Kaplan-Meier method. Outcomes (RRT initiation 
and all-cause mortality) were calculated as number of events and rates per 
person-years. Incidence rate ratios (IRRs) were used to compare outcome 
incidence beween baseline exposure levels for age, sex, CKD stage, proteinuria 
status, comorbidity and smoking status categorised as shown in table 1. To allow 
for the potential non-linear increase in IRR with change in categories of age, and 
other categorical exposures, these exposures were analysed using indicator 
variables. Outcomes by combined age groups 15-44, 45-54, 55-64, 65-74, 75-84 
and 85+ years were also calculated given the small numbers in the youngest age 
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bands and population mortality data only being available for the composite age 
85+ years.  Analyses, stratified separately by CKD stage, hypertension status and 
age were conducted to assess whether these modified the effect of other 
exposures e.g. gender. Poisson models were used to explore the effect of baseline 
characteristics on both outcomes separately. These were repeated with only those 
with a measurement of proteinuria to ensure there was no change in effect. 
 
Mortality rates were compared with age, sex strata specific mortality estimates 
for the whole Grampian population (estimated from the number of deaths 
registered and mid-year population estimates for years 2003 through 2009 (12, 
13)). These comparisons were expressed both as mortality rate excess and 
mortality rate ratios. 
 
To translate the risk data into information useful for supporting patient care, the 
percentage with incident RRT at 5 years by baseline age, sex, CKD stage and 
proteinuria status was also calculated. Similarly, to translate the competing risk 
of death, the percentages of the cohort that were still alive and not on RRT at 5 
years for these same categories were calculated.    
    
All analysis was carried out with Stata 11.1.   
 
 
 
 
 
Results 
 
Baseline 
The 3414 individuals had a median age of 78.6 years (interquartile range 71.1 to 
84.1 years), 44.2% were male (table 1). The majority (66.4%) had stage 3b CKD 
(figure 1). Reflecting clinical practice, in 70.5% there had been no laboratory 
quantification of urinary protein. Comorbidity was common – 40% had ischaemic 
heart disease and 25% diabetes at baseline. 
 
Outcomes 
At 6 years follow-up, 170 (5%) had initiated RRT (77 subsequently dying), 2024 
(59%) died without initiating RRT, and 1220 (36%) were alive without initiating 
RRT (see supplemental table 1). Of these 1220 survivors, only 51 had no contact 
with NHS Grampian within a year of study end. The characteristics of those 
initiating RRT or dying, are shown in table 2. There were 12,919 and 13,339 
patient-years of follow up for initiation of RRT and death respectively (420 
patient-years after initiating RRT).  
 
Renal replacement therapy 
Overall the chronic RRT initiation rate was 1.3 per 100 patient years, males at 
1.96 and females at 0.81 per 100 patient-years, respectively. Over the six years, 
the annual RRT initiation rates for reported risk factors were stable (results not 
shown). Initiation rates dropped with age from 14.33 to 0.65 per 100 patient-
years amongst those 15-25 years and 75-85 years at baseline respectively, with 
no-one initiating chronic RRT who was above 85 years at baseline (figure 2), the 
actual numbers initiating RRT however increased from 6 to 34 in these age 
groups, and was 49 in those aged 65-74 years. Both CKD stage and the presence 
of proteinuria were associated with RRT initiation rates (renal survival is shown in 
figure 3 and Poisson regression derived incidence rate ratios adjusted as 
appropriate in table 2). There was no evidence of modification of the effects 
outlined in table 2 when stratified by CKD stage, hypertension status and age 
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(results not shown), nor when the analyses were repeated without those with no 
measure of proteinuria (see supplemental table 2). 
  
Mortality 
All cause mortality rates were 15.6 and 15.9 per 100 patient-years in males and 
females respectively. Circulatory system diseases were recorded as the main 
cause of death in 1030 (49% - ICD-10, I00-I99), specifically ischaemic heart 
disease in 576 (28%). Mortality rates in the CKD cohort increased with age, from 
1.9 to 33.8 per 100 patient-years in those aged 15-45 years and over 85 years at 
baseline, compared to 0.1 and 16.5 per 100 patient-years in the general 
Grampian population. Mortality rates increased with worse CKD stage, most 
comorbidities, proteinuria and male sex (table 2). 
 
Translating into patient care 
The percentage of the cohort, stratified by sex, age band (<50, 50-69, ≥70 
years), proteinuria status (presence of macroalbuminuria or not 
(normoalbuminuria, microalbuminuria and un-measured)) and CKD stage, that 
had initiated RRT by 5 years is presented (figure 4) as a simple illustrative risk 
communication tool. This shows the variability by age even within a given sex, 
CKD stage, or proteinuria status group.  
The effect of age and sex on absolute and relative all-cause mortality rates in 
those with CKD is shown in figures 5 and 6. The 19-fold and 2-fold increase in 
mortality in those with CKD aged 15-45 years and 85 years and older respectively 
equates to 2 excess deaths per 100 patient-years amongst those aged 15-45, and 
17 excess deaths per 100 patient-years amongst those aged 85 years and over 
(shown separately by sex in figures 6 and 5 respectively). 
There were 1220 individuals in the GLOMMS-I cohort who neither died nor 
initiated RRT. The percentage of the cohort who were RRT-free and alive at 5 
years are shown in figure 7. 
 
 
 
 
Discussion 
 
In this large British community CKD cohort with ~13,000 patient-years of follow-
up, the rate of RRT initiation was 1.3 per 100 patient-years. Young male 
individuals with macroalbuminuria, type 2 diabetes and advanced CKD (stage 5) 
were at highest risk of initiating RRT, but the numbers initiating RRT were highest 
in the older age groups. Overall mortality was high, particularly amongst the 
elderly. However the relative mortality risk, comparing those with CKD to the 
general population was highest amongst the young. A third of our cohort were 
still alive and not on RRT after six years despite being quite elderly. This survivor 
group illustrate that despite the competing risks of death and RRT initiation, many 
with CKD will not suffer these events and planning for care of these individuals is 
important. 
 
Whether identified through opportunistic healthcare testing as part of routine 
clinical practice or through screening, the prognostic significance of CKD is a 
challenging message to communicate. Age, sex (14), CKD stage and proteinuria 
status are important predictors of outcome in CKD.  The low rate of progression 
to ESRD and RRT (5, 6) creates a clinical challenge when faced with interpreting 
low eGFR results both at the individual patient level and the population level for 
planning services. Figure 4, showing the proportion initiating RRT after 5 years, 
by age, sex, CKD stage and the presence of macroalbuminuria, offers a template 
for a tool for clinicians for informing patients of risk (personalised by their 
physician in light of disease course and interventions). It is similar to the tables 
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outlined by Hallan (15) and Levey (16) using excretory function and albuminuria, 
but here we add age and gender as important additional factors when 
determining the risk of initiation of RRT.   
 
In GLOMMS-I, we identified the cohort through routine laboratory data and thus 
patients were identified by opportunistic testing. Compared to key studies based 
on cohorts identified through population screening (5, 7), GLOMMS-I better 
reflects likely outcomes in clinical practice. However, the use of routine laboratory 
data introduced a potential source of bias with inclusion dependent on an 
indication for measuring renal function. Some with CKD will have been missed 
due to a lack of retesting to confirm chronicity; and the creatinine inclusion 
thresholds of 130 µmol/l and 150 µmol/l, limits the generalisability of the findings 
to those with more advanced CKD (stage 3b (eGFR 30-45 ml/min/1.73m2) or 
worse) particularly so amongst the elderly, however the insistence on at least 3 
months of depressed renal function ensures that those with just acute kidney 
injury are excluded. Many had not had a measurement of proteinuria and this 
potentially weakens the discriminatory effect that microalbuminuria may have 
had over normoalbuminuria if more information had been available. However 
since this information is missing in a non-random way (presumably not thought to 
be clinically relevant), no attempt to impute the results have been made. Indeed 
the exclusion of these individuals made little difference to the overall results. The 
use of secondary care documentation for comorbidity is a potential source of 
ascertainment bias, however case-note review by clinicians for pre-specified 
diagnostic criteria is an acceptable standard for comorbidity ascertainment. 
Grampian is a predominantly northern European Caucasian population and thus 
limits the generalisability of our findings. This cohort is important, however, 
because it reflects current clinical practice and is therefore very relevant to 
patients in care settings where there is opportunistic detection of CKD.  
Information on medication at baseline would have been ideal but was not 
available and is unlikely to have a huge effect over those of age and stage of 
renal disease. Although we adjusted for potential confounders, there might be 
additional confounders for which we were unable to correct. The illustrative tool is 
just illustrative, and has not been validated in other populations. Due to the small 
numbers in each risk category the estimates are imprecise, and volatile - any one 
young individual’s outcome has a large impact. 
 
Although other British studies have reported on mortality (19, 24, 29) and RRT 
initiation (19) in those with CKD, we believe that this is the largest British cohort 
to date reporting on both outcomes, with the longest follow-up time; however 
there are larger studies from elsewhere (6, 8, 18, 23, 26). The use of linked data, 
collected as part of routine care, provides an efficient methodology for the 
establishment and follow-up of a community cohort that reflects clinical practice. 
GLOMMS-I was carefully characterised at baseline with confirmation of chronicity, 
and case-note review for comorbidity. Because of the remoteness of the 
population there were few losses to follow-up; only 1.5% of the cohort had no 
documentation of initiating RRT, dying or having contact with NHS Grampian 
within a year of study end. Using all creatinine measurements to determine 
inclusion in the cohort ensured a community perspective of CKD, rather than 
focussing on those referred to secondary care. The accepted risk factors for 
progressive renal disease, type 2 diabetes and proteinuria, were associated with 
initiation of RRT. 
 
Routine eGFR reporting and the international acceptance of the principles of the 
KDOQI CKD definitions, has focused clinical attention on CKD.  CKD’s importance 
lies with its association with progression to end stage renal disease (ESRD), RRT 
initiation, increased mortality and cardiovascular disease. Reduced eGFR is 
common in the adult population, particularly the elderly, and some scepticism has 
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arisen about the appropriateness of labelling so many individuals with a disease 
(9). Although the rate and relative risk of RRT initiation is highest amongst the 
young, absolute numbers are higher amongst the older population. Registry data 
(17) shows that RRT incidence increases with age, however the risk of initiating 
RRT for those with CKD decreases (14, 18, 19). This reflects the increasing 
prevalence of CKD with increasing age (20-22), possibly differing renal pathology 
i.e. younger people with CKD may progress faster than elderly individuals, and 
probably more use of conservative care amongst those greater numbers of elderly 
with CKD. Whether this decreasing rate of initiation is due to progression rate, 
mortality, or differing acceptance rates (due to comorbidity and expected 
survival) with age is unclear. The association of worse CKD stage (18, 19) and 
proteinuria status (5, 6, 19, 23) with higher RRT initiation rates is clear. The 
association between comorbidity and RRT initiation rates is complex and open to 
ascertainment bias. Another study has illustrated that even for diabetes, the 
association with increased RRT initiation rates disappears after correction for 
eGFR and proteinuria (23).  We also found this, so although models adjusting for 
comorbidity were developed, they were dropped since they made little difference 
to model performance. 
 
Mortality in those with CKD is a far more common outcome than the initiation of 
RRT (6, 19), although in Nephrology clinics this may not be so (8). The relative 
importance of CKD for all-cause mortality, by age is less often illustrated (24, 
25). We found the relative risk of death in those with CKD compared to the 
general population was highest in the young; this may be due to a greater 
contribution to mortality from premature cardiovascular disease and non-
traditional cardiovascular risk factors in the young than the elderly, where 
cardiovascular disease is more widespread. However the absolute numbers dying 
were far higher in the elderly with CKD, with many more excess deaths per 100 
patient-years, a finding supported by Hallan et al (26) for cardiovascular 
mortality.  
 
The increase in mortality with worsening levels of excretory function (CKD stage) 
is a consistent finding (6, 7, 27-29) and in tandem with proteinuria status has 
been the focus of a recent patient level meta-analysis (30). This found, as did we, 
that increasing albuminuria and worsening eGFR is associated with increasing 
mortality risk, even amongst those with microalbuminuria. 
 
The contrast between relative and absolute risk for both RRT initiation and 
mortality by age group illustrate the challenge in planning CKD services to meet 
the individual (clinical) and population (public health) needs. A young person with 
CKD has a very high personal risk for both initiating RRT and death. However the 
societal costs for the small numbers involved is low. Whereas an elderly person 
with CKD has a very low risk of initiating RRT, and mortality risk just twice that of 
the general population, however the societal costs in terms of the numbers 
initiating RRT and dying are substantial. This study provides some simple 
illustrative tools as a template for clinicians for informing patients of risk and to 
inform service planning. The challenge that now faces clinicians is how to identify 
appropriately those amongst the elderly (the majority with CKD) who will benefit 
from intervention, and to investigate the non-fatal, non-RRT healthcare costs of 
CKD, the high rates of comorbidity complicate this further. It seems clear that all 
young people with CKD are at high risk and should be monitored carefully.  
Simple tools, aimed at supporting clinical care and service planning are an 
important element in translating the epidemiological understanding of CKD into 
practice. 
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Tables 
 
Table 1 - Baseline characteristics of GLOMMS-I CKD cohort 
 
CKD=chronic kidney disease; eGFR=estimated glomerular filtration rate; stage3=eGFR30-59ml/min/1.73m2; stage 4 = eGFR15-29 ml/min/1.73m2; stage 5 = 
eGFR<15ml/min/1.73m2.   
$ P value calculated for proportions using Chi squared test statistic, and distributions using Mann Whitney test 
^ General Register Office for Scotland (13) 
*Unless otherwise stated table is of the format N in group and (%) 
# Only 17 males and 1 female had stage 3a disease. 
†Criteria for ascribing comorbidities:- Ischaemic heart disease (IHD) = A history of angina, myocardial infarction, abnormal coronary angiogram, coronary 
angioplasty or coronary artery bypass grafting; Congestive cardiac failure (CCF)= Record of New York Heart Association criteria symptoms; peripheral vascular 
disease = a history of claudication, suggestive angiogram or tissue loss due to vascular disease; Cerebrovascular disease (CVD) = a diagnosis of transient 
ischaemic attack, stroke (with or without full recovery) or an abnormal CT scan in keeping with cerebrovascular disease; hypertension = either an in-patient or 
general practitioner (GP) diagnosis; dementia = a hospital consultant or GP diagnoses of dementia; Chronic obstructive pulmonary disease (COPD) = either a 
respiratory physician diagnosis, or supportive evidence such as pulmonary function tests and a non-respiratory physician diagnosis; Connective tissue disease = A 
diagnosis of rheumatoid arthritis, systemic lupus erythematosis, mixed connective tissue disease or similar, made by physicians used to managing these conditions 
(e.g. nephrologists, rheumatologists, respiratory physicians); Type 1 diabetes (DM type I)= diagnosis made by a diabetes clinic; Type 2 diabetes (DM type II) = 
diagnosis made by a diabetes clinic, or by a non-diabetes physician and treated initially with diet or oral hypoglycaemic agents; Chronic liver disease = a diagnosis 
of cirrhosis or chronic active hepatitis by a hepatologist, or by a non-hepatologist with supportive hepatic imaging or biopsy; non-haematological malignancy = Any 
diagnosis of non-haematological malignancy; Haematological malignancy = A diagnosis of haematological malignancy. 
‡Smoking status:- “Non-smoker” and “ex-smoker” status were defined based on record of these in the case notes up to the time of “index”. “Current smoker” 
status was assigned if there was a record of this up to 12 months post-index (if no earlier status was available). If none of these were recorded in the notes the 
smoking status was recorded as unknown. 
13 of 19 
 
Table 2 – Numbers, rates and incidence rate ratios for characteristics of those initiating RRT and for mortality in the GLOMMS-I cohort after 6 years follow-up 
 
CKD=chronic kidney disease; eGFR=estimated glomerular filtration rate; stage3=eGFR30-59ml/min/1.73m2; stage 4 = eGFR15-29 ml/min/1.73m2; stage 5 = eGFR<15ml/min/1.73m2; IRR=incidence rate ratio; CI=confidence interval.  * Including after initiating RRT 
Poisson regression used to derive incidence rate ratios (IRRs)
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Figure 1 – Number of patients in GLOMMS-I cohort by CKD stage at baseline 
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Figure 2 - Numbers and rates of patients initiating renal replacement therapy in GLOMMS-I 
cohort 
 
CKD=chronic kidney disease; RRT=renal replacement therapy.
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Figure 3 – Renal survival by CKD stage and level of albuminuria 
 
CKD=chronic kidney disease; eGFR=estimated glomerular filtration rate; stage3=eGFR30-59ml/min/1.73m2; stage 4=eGFR15-29 ml/min/1.73m2; stage 
5=eGFR<15ml/min/1.73m2; no macroalbuminuria=albumin creatinine ratio (ACR)<30mg/mmol, or protein creatinine ratio (PCR)<50mg/mmol, or urine not tested; 
macroalbuminuria=ACR≥30mg/mmol, or PCR≥50mg/mmol.  
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Figure 4 – Percentage initiating renal replacement therapy by 5 years for age, gender, CKD 
stage, and proteinuria level specific subgroups  
 
CKD=chronic kidney disease; eGFR=estimated glomerular filtration rate; stage3=eGFR30-59ml/min/1.73m2 (divided in the UK into stage 3a (45-69 
ml/min/1.73m2) and stage 3b (30-45 ml/min/1.73m2)); stage 4=eGFR15-29 ml/min/1.73m2; stage 5=eGFR<15ml/min/1.73m2; no macroalbuminuria=albumin 
creatinine ratio (ACR)<30mg/mmol, or protein creatinine ratio (PCR)<50mg/mmol, or urine not tested; macroalbuminuria=ACR≥30mg/mmol, or PCR≥50mg/mmol.  
For comparison, the percentage of the whole population that could be expected to have initiated RRT after 5 years (given an RRT initiation rate of 100 per million 
population) is estimated as 0.05%. 
* There were only 18 patients with stage 3a CKD (45-69 ml/min/1.73m2) therefore results not presented. 
^ There were no individuals in this group. Numbers for macroalbuminuria subgroups:- male<50, 23; male50-69, 70; male>70, 82; female<50, 22; female 50-69, 
37; female >70, 79. Numbers for those without macroalbuminuria or where it had not been measured at baseline:- male<50, 35; male50-69, 266; male>70, 
1017; female<50, 30; female 50-69, 259; female >70, 1476. 
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Figure 5 - GLOMMS-I mortality rate in excess of background population by age and sex 
 
15.3
9.7
5.2
4.4
3.1
2.2
25.7
16.2
11.4
5.8
3.1
2.0
Male
Female
1
1
0
1
0
0
M
o
rt
a
lit
y
 r
a
te
 r
a
ti
o
 G
L
O
M
M
S
-I
 /
 G
ra
m
p
ia
n
 p
o
p
u
la
ti
o
n
15-44* 45-54 55-64 65-74 75-84 85+
Age group at baseline (years)
* Age groups combined due to small numbers
 
Figure 6 - Relative mortality risk in the GLOMMS-I cohort compared to the background 
population by age and sex 
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Figure 7 - Percentage of GLOMMS-I cohort alive and not on RRT by 5 years for age, gender, 
CKD stage, and proteinuria level specific subgroups  
 
 
CKD=chronic kidney disease; eGFR=estimated glomerular filtration rate; stage3=eGFR30-59ml/min/1.73m2 (divided in the UK into stage 3a (45-69 
ml/min/1.73m2) and stage 3b (30-45 ml/min/1.73m2)); stage 4=eGFR15-29 ml/min/1.73m2; stage 5=eGFR<15ml/min/1.73m2; no macroalbuminuria=albumin 
creatinine ratio (ACR)<30mg/mmol, or protein creatinine ratio (PCR)<50mg/mmol, or urine not tested; macroalbuminuria=ACR≥30mg/mmol, or PCR≥50mg/mmol.  
* There were only 18 patients with stage 3a CKD (45-69 ml/min/1.73m2) therefore results not presented. 
^ There were no individuals in this group. Numbers for macroalbuminuria subgroups:- male<50, 23; male50-69, 70; male>70, 82; female<50, 22; female 50-69, 
37; female >70, 79. Numbers for those without macroalbuminuria or where it had not been measured at baseline:- male<50, 35; male50-69, 266; male>70, 
1017; female<50, 30; female 50-69, 259; female >70, 1476. 
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